Myocardial Infarction (MI), Stroke
Conditions
Brief summary
To assess the diagnostic accuracy of a smartphone application in predicting heart attack or stroke within 3-4 days in high-risk patients.
Interventions
DEVICESmartphone application Antshrike
All participants will wear a smart watch that has an application Antshrike, which will collect demographic data, health history, lifestyle factors, and biobehavioral data for 18 months.
Sponsors
Stanford University
Before Health Intelligence Ltd
Samsung Electronics Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 79 Years
Healthy volunteers
Yes
Inclusion criteria
1. Be able to provide electronic or written informed consent and be able to effectively communicate and understand the study procedures, risks, and required activities. 2. Age 40 to 79 years. 3. Be willing to wear a smartwatch continuously for 18 months and comfortable with using wearable devices or other technologies that monitor their data over time. 4. Established ASCVD or at an increased risk for a first MACE (i.e., no prior major ASCVD event), defined as anyone of the following: i) Evidence of atherosclerotic CAD on CT or invasive coronary angiogram defined as a coronary artery stenosis ≥ 20% but \<50% in the left main coronary artery or a stenosis ≥ 20% but \<70% in any other major coronary artery. ii) Coronary artery calcium score ≥ 100 Agatston units. iii) High estimated10-year ASCVD risk ≥ 20% by pooled cohort equation. iv) Intermediate estimated 10-year ASCVD risk 7.5% to \<20% by pooled cohort equation with at least 2 of the following risk-enhancing factors: 1. A first degree relative with history of premature ASCVD (males, age \<55 years; females, age \<65 years). 2. History of premature menopause before age 40. 3. History of maternal pregnancy complications (defined as a history of either preeclampsia, gestational hypertension, or gestational diabetes). 4. South Asian ancestry. 5. Chronic inflammatory disorders (defined as either rheumatoid arthritis, systemic lupus erythematosus, psoriasis covering ≥10% of body surface area, Crohn's disease, ulcerative colitis, or HIV/AIDS). 6. High-sensitivity C-reactive protein (hsCRP) ≥2 mg/L documented in the 12 months preceding the screening visit, and, in absence of any underlying acute or inflammatory conditions. 7. Lipoprotein (a) ≥50 mg/dL or ≥125 nmol/L at any time before the screening visit. 8. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2. 9. Ankle branchial index (ABI) \<0.9 with no symptoms of intermittent claudication. 10. Metabolic syndrome: increased waist circumference, elevated triglycerides, elevated blood pressure, elevated glucose, and low HDL-C are factors i. Diabetes
Exclusion criteria
1. The 10-year ASCVD risk \<7.5%. 2. Elevated troponin at baseline. 3. Cognitive impairment. 4. Neurological disorders that would impair their ability to provide informed consent or adhere to study protocols. 5. Metastatic cancer or active cancer undergoing chemotherapy. 6. Terminal illness. 7. Pregnant women or women of childbearing potential not using contraception. 8. Current or past major psychiatric disorders (e.g., schizophrenia, bipolar disorder, severe depression) that could affect physiological or biometric data. 9. Surgical or medical condition, which in the opinion of the Investigator, may place the participant at higher risk from his/her participation in the study, or is likely to prevent the participant from complying with the requirements of the study or completing the study. 10. Unwillingness or inability to comply with study procedures, including adherence to study visits, fasting blood draws and compliance with study protocol. 11. Residing in an inpatient facility or bedbound
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of ASCVD events | Baseline through 18 months | ASCVD events include myocardial infarction (MI), ischemic stroke/transient ischemic attack (TIA), CV death, or clinically driven arterial revascularization or hospitalization. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSandra Tsai, MD
Stanford University
Outcome results
None listed